T1	CHEM 57 76	Ozuriftamab Vedotin
T2	CHEM 78 84	BA3021
T3	CHEM 112 121	Nivolumab
#1	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	LIVB 125 134	pacientes
#2	AnnotatorNotes T4	C0030705; Patients; Patient or Disabled Group
T5	DISO 139 154	tumores sólidos
#3	AnnotatorNotes T5	C0280100; Solid Neoplasm; Neoplastic Process
T6	CHEM 246 265	ozuriftamab vedotin
T7	CHEM 267 273	BA3021
T8	PROC 278 289	monoterapia
#4	AnnotatorNotes T8	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T9	CHEM 311 320	nivolumab
#5	AnnotatorNotes T9	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	LIVB 324 333	pacientes
#6	AnnotatorNotes T10	C0030705; Patients; Patient or Disabled Group
T11	DISO 338 353	tumores sólidos
#7	AnnotatorNotes T11	C0280100; Solid Neoplasm; Neoplastic Process
T12	DISO 397 412	Tumores sólidos
#8	AnnotatorNotes T12	C0280100; Solid Neoplasm; Neoplastic Process
T13	LIVB 463 472	pacientes
#9	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	DISO 492 523	cáncer de pulmón no microcítico
#10	AnnotatorNotes T14	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T15	Neg_cue 509 511	no
T16	Negated 512 523	microcítico
T17	DISO 525 529	CPNM
#11	AnnotatorNotes T17	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T18	DISO 533 541	melanoma
#12	AnnotatorNotes T18	C0025202; melanoma; Neoplastic Process
T19	DISO 577 588	metastásico
#13	AnnotatorNotes T19	C4255448; Metastasis; Pathologic Function
T20	PROC 601 630	histológica o citológicamente
T21	Age 639 647	≥18 años
T22	PROC 651 664	Función renal
#14	AnnotatorNotes T22	C0232804; Renal function; Organ or Tissue Function
T23	PROC 677 693	Función hepática
T24	PROC 706 726	Función hematológica
T25	Duration 847 863	al menos 3 meses
T26	DISO 892 903	Cardiopatía
#15	AnnotatorNotes T26	C0018799; Heart Diseases; Disease or Syndrome
T27	DISO 947 957	metástasis
#16	AnnotatorNotes T27	C0027627; Neoplasm Metastasis; Neoplastic Process | C2939419; Secondary Neoplasm; Neoplastic Process
T28	Neg_cue 958 961	sin
T29	Negated 962 1002	controlar en el sistema nervioso central
T30	ANAT 978 1002	sistema nervioso central
#17	AnnotatorNotes T30	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T31	PROC 1006 1017	Tratamiento
#18	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	CHEM 1032 1058	derivado de la auristatina
T33	Neg_cue 1072 1075	sin
T34	Negated 1076 1084	conjugar
T35	CHEM 1137 1142	vinca
T36	DISO 1162 1182	reacciones alérgicas
#19	AnnotatorNotes T36	C0020517; Hypersensitivity; Pathologic Function | C1527304; Allergic Reaction; Pathologic Function
T37	PROC 1198 1209	tratamiento
#20	AnnotatorNotes T37	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T38	CHEM 1214 1217	AcM
#21	AnnotatorNotes T38	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T39	Spec_cue 1240 1251	sospecha de
T40	DISO 1252 1259	alergia
#22	AnnotatorNotes T40	C0020517; Hypersensitivity; Pathologic Function
T41	Speculated 1252 1259	alergia
T42	DISO 1262 1274	intolerancia
T43	Speculated 1262 1274	intolerancia
T44	CHEM 1295 1307	medicamentos
#23	AnnotatorNotes T44	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T45	PROC 1375 1404	intervención de cirugía mayor
T46	PROC 1463 1477	administración
#24	AnnotatorNotes T46	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T47	CHEM 1481 1487	BA3021
T48	PROC 1531 1579	pruebas del virus de la inmunodeficiencia humana
T49	DISO 1581 1584	VIH
#25	AnnotatorNotes T49	C0458074; Human immunodeficiency virus (HIV) status; Finding
T50	DISO 1602 1641	síndrome de inmunodeficiencia adquirida
#26	AnnotatorNotes T50	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T51	DISO 1643 1647	sida
#27	AnnotatorNotes T51	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T52	PHYS 1688 1697	lactancia
T53	LIVB 1652 1671	Mujeres embarazadas
T54	Duration 1429 1438	4 semanas
T55	PROC 187 242	Estudio de fase 1/2 de aumento y ampliación de la dosis
T56	Quantifier_or_Qualifier 86 90	solo
T57	Quantifier_or_Qualifier 155 164	avanzados
T58	Quantifier_or_Qualifier 357 373	estadio avanzado
T59	Quantifier_or_Qualifier 416 432	estadio avanzado
T60	Quantifier_or_Qualifier 542 561	localmente avanzado
T61	Observation 563 574	irresecable
T62	Observation 651 673	Función renal adecuada
T63	Quantifier_or_Qualifier 694 702	adecuada
T64	Observation 706 735	Función hematológica adecuada
T65	CONC 772 806	Eastern Cooperative Oncology Group
T66	CONC 808 812	ECOG
T67	Result_or_Value 817 822	0 o 1
T68	CONC 826 843	Esperanza de vida
T69	Quantifier_or_Qualifier 904 930	clínicamente significativa
T70	CONC 962 971	controlar
T71	Quantifier_or_Qualifier 1060 1069	conjugado
T72	CONC 1076 1084	conjugar
T73	Quantifier_or_Qualifier 1186 1194	grado ≥3
T74	Result_or_Value 1507 1527	resultados positivos
T75	Patient 125 134	pacientes
T76	Patient 324 333	pacientes
T77	Patient 463 472	pacientes
T78	History_of 1006 1017	Tratamiento
T79	History_of 1032 1058	derivado de la auristatina
T80	History_of 1162 1182	reacciones alérgicas
T81	History_of 1252 1259	alergia
T82	History_of 1262 1274	intolerancia
T83	History_of 1375 1404	intervención de cirugía mayor
T84	History_of 1543 1579	virus de la inmunodeficiencia humana
T85	History_of 1581 1584	VIH
T86	History_of 1602 1641	síndrome de inmunodeficiencia adquirida
T87	History_of 1643 1647	sida
T88	Patient 1652 1697	Mujeres embarazadas o en período de lactancia
